Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,919 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% sodium chloride (normal saline) Clear all
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

NCT04095858
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Interventions
Efprezimod alfa, Placebo, Methotrexate, Tacrolimus
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 4 Interventional

The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

NCT06450392
View directory record Official record
Conditions
Orbital Edema, Orbital Ecchymosis
Interventions
Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection, normal saline - intravenous
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 10, 2026, 1:33 PM EDT
Withdrawn Phase 1 Interventional

Pulmozyme for Sjogren's Associated Cough

NCT01357447
View directory record Official record
Conditions
Sjogren's Syndrome, Cough
Interventions
Dornase alfa, Saline
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

NCT02665364
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
IFNα-Kinoid, Placebo, ISA 51 VG
Biological · Other
Lead sponsor
Neovacs
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
View directory record Official record
Conditions
COVID-19
Interventions
RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 3 Interventional

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

NCT06376916
View directory record Official record
Conditions
Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

NCT04471038
View directory record Official record
Conditions
Influenza Type A, Influenza Type B, Influenza
Interventions
SAB-176, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity

NCT00947284
View directory record Official record
Conditions
Healthy
Interventions
nalbuphine plus naloxone, nalbuphine plus saline, naloxone plus saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

NCT06692907
View directory record Official record
Conditions
Escherichia Infection
Interventions
B7A (ETEC challenge strain), CssBA, dmLT, Placebo
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 3 Interventional

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

NCT04799249
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Trilaciclib, Placebo, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

NCT03389555
View directory record Official record
Conditions
Sepsis, Septic Shock, Metabolic Disturbance
Interventions
vitamin C, vitamin B1, hydrocortisone, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

NCT02664909
View directory record Official record
Conditions
Femoral Neck Fractures
Interventions
Tranexamic Acid, Placebo (saline)
Drug
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 4 Interventional Results available

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents
Drug · Other · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 10, 2026, 1:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

NCT01021865
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus Type 2
Interventions
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge

NCT00671593
View directory record Official record
Conditions
Atopic Asthma, Healthy
Interventions
House Dust Mite, Diluent
Biological
Lead sponsor
John Sundy
Other
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 1 Interventional

Toradol (Ketorolac) in Breast Surgery to Reduce Pain & Opioid Use

NCT04439396
View directory record Official record
Conditions
Breast Reduction, Breast Reconstruction
Interventions
Ketorolac Tromethamine, Saline
Drug · Other
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables

NCT03054922
View directory record Official record
Conditions
Anesthesia
Interventions
Normal Saline, Lactated Ringer, Normosol-R Inj
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication

NCT01976845
View directory record Official record
Conditions
Elective Orthopedic Surgery
Interventions
Midazolam, Propofol, Saline
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

NCT00565929
View directory record Official record
Conditions
Variola Major (Smallpox)
Interventions
Placebo, MVA-BN
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 10, 2026, 1:33 PM EDT
Not listed Not applicable Interventional

Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain

NCT01905137
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Intervention-Botulinum Toxin Type A, placebo
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa

NCT02805595
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
23.4% Hypertonic saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 10, 2026, 1:33 PM EDT